Shares of Be­yond­Spring sky­rock­et on new, pos­i­tive can­cer drug tri­al re­sults

Some­times re­sults come along that shock even a biotech’s be­liev­ers.

On Wednes­day, Be­yond­Spring, a small New York biotech with an off­beat ap­proach to im­munother­a­py, an­nounced its lead drug sig­nif­i­cant­ly ex­tend­ed non-small cell lung can­cer pa­tients’ lives in a large tri­al. Al­though the com­pa­ny did not re­lease the ex­act sur­vival da­ta, it said that near­ly twice as many pa­tients were alive af­ter two years on the drug arm than on the stan­dard-of-care arm.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN